Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03519659
Other study ID # RP0308/2014H0437
Secondary ID R01CA195513
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date July 21, 2015
Est. completion date December 31, 2024

Study information

Verified date January 2024
Source University of Cincinnati
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess new low radiation dose techniques for clinical PET/CT scans through intra-individual comparison between a clinical, standard dose scan and a low-dose scan, completed within one week of each other.


Description:

Positron Emission Tomography/Computed Tomography (PET/CT) imaging using 18F-FDG is an important, commonly used cancer, neuroscience and cardio-vascular imaging methodology to detect disease and to monitor therapeutic interventions. While considerable technological progress of PET/CT systems has occurred over the last decade, we have not re-evaluated the ability to potentially reduce the radiation burden of the used PET imaging pharmaceutical (FDG). This early phase trial intends to accomplish the following: - to validate that the radiation dose burden from the PET imaging pharmaceutical (FDG) can be reduced by more than 50% from the current standard of clinical care (SOC) level without affecting the diagnostic ability; - to confirm that a low dose approach will be feasible for response assessment; - to validate that the difference in FDG uptake between imaging 60 min +/- 10 min post injection and 75 min +/- 10 min post injection is independent/equivalent of the injected FDG dose - to validate a simulation methodology to streamline future dose finding studies for PET imaging pharmaceuticals.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 190
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male and female patients greater than or equal to 18 years of age - Patients scheduled for a standard of care PET/CT scan - For female patients of child-bearing potential, the OSUWMC requirements for receiving the standard of care PET imaging agent and CT examination needs to be met Exclusion Criteria: - Participants who are pregnant or lactating - Prisoners - Participants incapable of giving informed consent - Patients unable to lie flat on the scanner for extended periods of time

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
PET/CT scan with 13 mCi radiation dose
13 mCi 18F-FDG dose
PET/CT scan with 5 mCi radiation dose
5 mCi 18F-FDG dose
PET/CT scan with 2.5 mCi radiation dose
2.5 mCi 18F-FDG dose
PET/CT Scan with 6.5 mCi radiation dose
6.5 mCi 18F-FDG dose
PET/CT Scan with not yet determined radiation dose
We plan for the possibility that one of the three-Sub-Studies (A-B) would not demonstrate equivalency, and we would then perform a modified protocol in which the SOC dosing is compared to a lower and higher dose than originally tested.

Locations

Country Name City State
United States The Ohio State University Wexner Medical Center Columbus Ohio

Sponsors (3)

Lead Sponsor Collaborator
University of Cincinnati National Cancer Institute (NCI), Ohio Third Frontier

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Image quality assessed by blinded readers through study completion, on average 2-5 years
Secondary Artifacts assessed by blinded readers through study completion, on average 2-5 years
Secondary Lesion detectability assessed by blinded readers through study completion, on average 2-5 years
Secondary Image noise assessed by blinded readers through study completion, on average 2-5 years
See also
  Status Clinical Trial Phase
Recruiting NCT05549024 - 68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients Early Phase 1